Axonics receives regulatory approval for recharge-free SNM system in Australia

Axonics “announced that it has received regulatory approval from the Therapeutic Goods Administration for marketing the Axonics F15 recharge-free sacral neuromodulation system in Australia to treat adults with overactive bladder. Axonics commenced SNM commercial activities in Australia in March 2023. In Australia, in addition to its SNM products, Axonics markets Bulkamid, the company’s unique hydrogel indicated for female stress urinary incontinence.”